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PPOpatients compared to other groups. Future analyses should determinewhether
insurance coverage is associated with access to medical care and subsequent clin-
ical and HRQOL outcomes. These results serve as a baseline reference.
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OBJECTIVES: The use of administrative datasets can be a useful tool in cancer
surveillance by providing disease patterns, utilization of services, and patient char-
acteristics. This study explores characteristics of treatment and staging among
lung cancer patients in the US using hospital-based services. METHODS: A cross-
sectional study of chemotherapy treated lung cancer patients receiving in or out-
patient services from hospitals in MedAssets’ health data from July 1, 2010 to June
30, 2011 were assessed for staging and treatment characteristics. The Thomas, et
al. staging algorithm was applied to patient services to estimate stage of lung
cancer. Descriptive statistics were calculated for the sample by stage, treatment
characteristics, procedures and hospital characteristics. Patterns of care were tab-
ulated and compared by cancer stage. RESULTS: The sample included 14,628
unique patients who received chemotherapy during the study period spanning
over 217,000 hospital visits. The majority (75%) of hospital visits were classified as
stage 1-2 compared to stage 3-4 (25%). Stage 1-2 patients experienced fewer hospi-
tal visits (5.9 vs. 12.5, p 0.0001) and had a significantly higher proportion of inpa-
tient stays (22.1% vs. 6.7%, p 0.0001). Most visits (88.7%) occurred in hospital-
based outpatient facilities. There were 52,289 (3.1 visits per patient) chemotherapy
related visits. Primary chemotherapies included: pemetrexed disodium (16.2 %),
carboplatin (34.3%) and cisplatin (11.0%). Blood transfusions and other non-surgi-
cal procedures made up the largest portion (25.4%) of all procedures performed on
both groups. Finally, both groups were treated in primarily in large (300 beds,
75.1%), urban (90.1%), and teaching (59.1%) hospitals. CONCLUSIONS: The cross-
sectional analysis demonstrates the possible value of large-scale administrative
data sets in illuminating differences in treatment characteristic in a chemothera-
py-treated lung cancer population. Future analysis should evaluate the use of these
data to help predict utilization and treatment patterns in larger populations.
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OBJECTIVES: To describe treatment patterns by lines of systemic (drug) therapy in
patients with metastatic melanoma in the United States.METHODS: Using a large
USmedical claims database, patients were identified between 2005 and 2010 using
2 melanoma diagnoses (ICD-9-CM: 172.xx, V10.82) and 2 diagnoses for metas-
tasis (ICD-9-CM: 197.xx, 198.xx). Patients were followed from the metastatic diag-
nosis date to death, disenrollment, or end of study period (6/30/2010), whichever
occurred first. Lines of systemic therapy were identified based on the temporal
order, gaps, and changes in the drug regimens. Systemic therapies and the dura-
tion of therapy in each line were examined. RESULTS: A total of 2546 patients with
metastaticmelanomawere included and 985 (38.7%) received systemic therapy. As
the first documented therapy after diagnosis, 82.4% of patients received mono-
therapy (38.5% temozolomide, 14.3% interleukin-2, 11.4% interferon alfa-2b, 8.2%
dacarbazine, 2.9% paclitaxel, 2.5% GM-CSF) and 9.4% received carboplatin plus pa-
clitaxel. Mean duration of mono-therapy was 60 days, ranging from 32 days on
interleukin-2 to 124 days on GM-CSF. Of 287 patients (29.1% of previously treated)
received subsequent therapy, 68.0% received mono-therapy (26.8% temozolomide,
11.9% interleukin-2, 10.5% dacarbazine, 8.4% paclitaxel, 3.1% interferon alfa-2b,
1.7% GM-CSF), 16.7% carboplatin plus paclitaxel, and 7.3% dacarbazine-containing
therapies. Mean duration of mono-therapy was 67 days, ranging from 30 days on
interleukin-2 to 238 days on GM-CSF. Among 71 patients who further received
additional therapy, mono-therapy was still the dominant regimen (63.4%) with
21.1% temozolomide, 18.3% paclitaxel, 8.5% interleukin-2, 5.6% dacarbazine, 4.2%
GM-CSF, and 1.4% interferon alfa-2b. Carboplatin plus paclitaxelwas given to 19.7%
of patients. Mean duration of mono-therapy was 63 days, ranging from 7 days on
interferon alfa-2b to 90 days on temozolomide. CONCLUSIONS: The majority of
patients with advanced melanoma didn’t receive systemic therapy as captured in
the claims database; among those who received systemic therapy, mono-therapy
was most common.
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OBJECTIVES: To identify treatment patterns of care in patients with unresectable
stage III or stage IV melanoma disease in three public hospitals in Mexico.
METHODS: Retrospective longitudinal study that includes 102 adult patients with
unresectable stage III (any T, N1, M0) or stage IV (any T, any N, M1) melanoma,
diagnosed and treated from 2007 to 2010, at three specialty public hospitals in
Mexico (Centro Médico Nacional Siglo XXI, Hospital General de Mexico and Insti-
tuto Nacional de Ciencias Médicas y Nutrición). Patient characteristics and re-
source utilization were reported for each stage of treatment (diagnosis, first line
treatment, and second line or palliative care) and includes consultations, labora-
tory tests, hospitalization, surgery, hematologic support, radiotherapy and sys-
temic treatment. RESULTS: The mean age at time of diagnosis was 60.44 years old
CI(56.88-64.00) and a men-women ratio of 1.17:1, 86% in clinical stage III and 14%
stage IV. The total cost of diagnosis was $15,628.10 CI($9,329.07-$21,927.14), which
includes: consultations $4,225.96 CI($3,423.20-$5,028.72), laboratory tests $5,930.40
CI($3,768.31-$8,092.49), and hospitalizations $5,471.74 CI($1,188.12-$9,755.37). Dur-
ing first line treatment, 44.9% of all cases report hospitalization, 21.8% radiother-
apy, 69.2% surgery and 76.9% systemic therapy (Dacarbazine 28.8%, Interferon-
66.1% and Temozolomide 5.1%), with a total cost of $76,162.57 ($64,771.54-
$87,553.59). Only 37.2% report a second line treatment, with a mean cost of
$25,816.83 CI($21,638.70-$29,994.97), the systemic treatment (monotherapy or
combined) included CDDP 11.5%, Dacarbazine 61.5%, Interferon- 19.2%, Paclitaxel
11.5%, Carboplatin 3.8% and Vinorelbine 3.8. CONCLUSIONS: In this study, 76.9% of
the patients received first line systemic treatment, and only 37.2% received a sec-
ond line active treatment or palliative care. The lack of active treatment could be
associated with a poor performance status in these patients, as well as a lack of
availability of effective drugs for the treatment of unresectable stage III or stage IV
melanoma in the public Mexican hospitals.
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OBJECTIVES: To explore physician specialty patterns for the treatment of hepato-
cellular carcinoma (HCC). METHODS: Medicare patients diagnosed with HCC in
2000-07 with1 claim for HCC-related physician visits post-diagnosis were stud-
ied through 2009 using SEER-Medicare data. Transplant patients were excluded.
Visits by specialists seenwithin 4weeks of diagnosis and by therapywithin the first
treatmentweekwere explored. Specialties: Gastroenterology (GE), General/Family/
Geriatric/Internal (GF), Diagnostic/Intervention radiology (DIR), Hematology/Med-
ical oncology (HMO), General surgery/Surgery oncology (GSO), Radiation oncology
(RO), Multispecialty clinic/group practice (MG), Others. Therapies (non-mutually
exclusive): surgical resection, percutaneous ablation, transarterial chemoemboli-
zation (TACE), bland embolization, systemic chemotherapy, selective internal ra-
diation therapy, external beam radiation therapy. We examined second-line ther-
apy, specialists seen since week 5, and multiple-specialty visits as related to
multiple-first-line therapies. RESULTS: Of 6472 patients with1 specialist, 25%
saw GE, 10.5%GF, 23% DIR, 28%HMO, 16% GSO, 4% RO, 5.5%MG, and 66%Other; 52%
saw1 specialist type within 4 weeks of diagnosis, 5%none until after 4 weeks; 6%
had a resection as first line, 8%ablation, 9%TACE, 0.7%TAE, 9%chemo, 1%SIRT,
8%EBRT; 64% were untreated; 46% of patients saw only 1 specialist type in the first
4 weeks and 4% got 1 therapy form in the first treatment week. The specialties
distributions did not differ across first-line therapies. Other specialists were seen
by 65% of patients. GE and HMO were the most common specialty: 21-29% of pa-
tients sawGE and 23-37% sawHMO, 20-24%DIR, 11-17%GSO, 9-13%GF, 4-6%RO, and
1%MG, across therapies. Of the 2819 patients who saw only 1 type of specialist in
the first 4 weeks, 52% visited Others, 13%GE, 11%HMO, 10%DIR, 6%GSO, 5%GF,
4%RO, and 0.4%MG. CONCLUSIONS: HCC patients commonly see Gastroenterolo-
gists and Hematologists/Medical oncologists within 4 weeks of HCC diagnosis.
There was no clear HCC treatment pattern by specialist type.
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OBJECTIVES: Observational data of chronic myelogenous leukemia (CML) patients
is difficult to obtain outside of a randomized clinical trial (RCT) setting. A retrospec-
tive research registry was developed to evaluate the outcomes of CML treatment
decisions.METHODS: The CML cohort was created through amaster patient index
(MPI) across the Huntsman Cancer Institute, University Hospital, and Outpatient
Clinics. Patient records (1995 – 2010) were included with CML ICD-9 codes (250.1,
205.10-12); age  18; a listing in the Utah Population Database; and chart review,
including physician notes and laboratory results, indicative of CML. RESULTS: A
total of 234 patients had confirmed CML (140 males, 59.8%). Mean age at diagnosis
was 46 (SD 15.1). Of those, 211 subjects (90.2%) were diagnosed in chronic phase
(CP), 12 (5.1%) in accelerated phase and 5 (2.1%) in blast phase (BP) with 15.5 (me-
dian; 14.6 mean, SD 4.2) CML cases diagnosed per year. Baseline lab results and
comorbidity scores were not statistically significantly different by stage, except for
an elevated platelet count in BP (p0.01). First line treatment was a tyrosine kinase
inhibitor for 51.3% overall, and 77.1% in new cases from 2001. Bone marrow trans-
plantwas utilized in 16.7%of patients overall. After 10 years, overall survival for the
CML cohort was 59.5%. Overall survival was 84.8% for patients diagnosed in CP and
treated with imatinib, 63.1% for patient’s receiving BMT and 41.4% for patients
treated with interferon-alpha. The most common cause of death overall was CML
(45.1%); in those receiving imatinib 38.9% died from CML. CONCLUSIONS: Clinical
outcomes data integrated via a MPI across a comprehensive research database to
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